Risk of differentiation syndrome with enasidenib, warns US FDA

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1732卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55460-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：4 / 4

相关论文

共 50 条

[21] US FDA Commissioner warns of "devastating" impact of funding cuts
不详
[J]. FUTURE MEDICINAL CHEMISTRY, 2011, 3 (06) : 644 - 644
[22] US FDA warns of serious risks with psoriasis drug Raptiva®
不详
[J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (04) : 393 - 394
[23] US FDA warns that stopping Gilenya can worsen MS
[J]. Reactions Weekly, 2018, 1730 (1) : 5 - 5
[24] US FDA warns of serious risks with psoriasis drug Raptiva®
不详
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (03) : 229 - 229
[25] Brazilian diet pills may be harmful, warns US FDA
[J]. Reactions Weekly, 2006, 1085 (1) : 3 - 3
[26] US FDA warns of injection-site reactions with naltrexone
[J]. Reactions Weekly, 2008, 1216 (1) : 5 - 5
[27] FDA warns of risk of intrathecal injection of tranexamic acid
[J]. Reactions Weekly, 2020, 1835 (1) : 1 - 1
[28] Vinpocetine during pregnancy: FDA warns of safety risk
[J]. Reactions Weekly, 2019, 1757 (1) : 8 - 8
[29] Antipsychotics a risk to neonates during pregnancy warns FDA
[J]. Reactions Weekly, 2011, 1341 (1) : 2 - 2
[30] FDA warns of potential risk from donor tissues
Fox, Steven
[J]. INFECTIONS IN MEDICINE, 2006, 23 (10) : 458 - 458

← 1 2 3 4 5 →